Latest Industry News & Trends
Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.
Recently Added News
Lilly, MeiraGTx Sign Ophthalmic Gene Therapy Deal Worth Up to $475 Million
MeiraGTx Holdings announced Nov. 10 that it granted drugmaker Eli Lilly exclusive worldwide rights to its AAV-AIPL1 gene therapy program targeting Leber congenital amaurosis 4 (LCA4). Lilly will al...
Q3-2025 Ophthalmic Revenue Roundup for Alcon, Santen, Immunocore, STAAR, Harrow, and Five Others
Alcon reported Nov. 11 that its Q3-2025 net sales totaled $2.6 billion, a 6 percent increase over $2.4 billion in Q3-2024. Surgical net sales for implantables, consumables, and equipment/other were...
Sydnexis Gains UK Approval for Low-Dose Atropine Drops in Pediatric Myopia
Sydnexis announced Nov. 6 that the UK’s Medicines and Healthcare Products Regulatory Agency had granted marketing authorization for Ryjunea, the company’s low-dose atropine formulation for slowing ...
STAAR Solicits New Bids Under Amended Deal with Alcon, Moves Shareholder Vote to Dec. 19
STAAR Surgical reported Nov. 7 that it had amended its merger agreement with Alcon to allow STAAR to solicit new buyers for 30 days under a new “go-shop” period ending Dec. 6. STAAR also delayed to...
Richard Pazdur, MD, to Lead US FDA’s Center for Drug Evaluation and Research
The US FDA reported Nov. 11 that oncologist Richard Pazdur, MD, had been named director of the Center for Drug Evaluation and Research (CDER). Pazdur is a 26-year veteran of the FDA and the foundin...
UK High Court Ruling Paves Way for Launch of Alvotech’s Aflibercept Biosimilar
Iceland’s Alvotech announced Nov. 10 that the UK High Court had rejected an injunction from Eylea marketers Regeneron and Bayer against Alvotech and its contract manufacturing organization. The dec...
Kwangdong Submits NDA in South Korea for Tenpoint’s Presbyopia Drop
Tenpoint Therapeutics announced Nov. 5 that Kwangdong Pharmaceutical had submitted a new drug application (NDA) to the Ministry of Food and Drug Safety in South Korea for Brimochol PF, a combinatio...
Mallinckrodt Spins Off Generics Business, Rebrands as Keenova
Drugmaker Mallinckrodt announced Nov. 10 that it had completed the planned spinoff of its Par Health generic pharmaceuticals and sterile injectables businesses and had rebranded as Keenova Therapeu...
PolyActiva, RareSight to Collaborate on Rare Pediatric Retinal Diseases
Australia’s PolyActiva announced Nov. 5 that it would collaborate with RareSight, of Menlo Park, California, an ophthalmology-focused life sciences company committed to advancing therapies for rare...
CMS’ Changes to Final 2026 Physician Fee Schedule Include Two Significant Cuts
The Centers for Medicare and Medicaid Services (CMS) made two significant cuts to parts of the formula used to calculate physicians’ Medicare procedure fees in 2026, despite heavy lobbying by the m...
Viridian Submits BLA to US FDA for Veligrotug in Thyroid Eye Disease
Viridian Therapeutics announced Nov. 3 that it had submitted a biologics license application (BLA) to the US FDA for veligrotug, the company’s intravenous treatment candidate for thyroid eye diseas...
4DMT Licenses Retinal Gene Therapy Candidate to Otsuka for Asia-Pacific
4D Molecular Therapeutics announced Oct. 30 a strategic partnership with Otsuka Pharmaceutical Co. to develop and commercialize retinal gene therapy candidate 4D-150 in the greater Asia-Pacific (AP...
Past News Stories
Q3-2025 Ophthalmic Revenue Roundup for Amgen, AbbVie, Hoya, Glaukos, Apellis, Astellas, and Four Others
Amgen, of Thousand Oaks, California, reported Nov. 4 that its Q3-2025 revenue from Tepezza was $560 million, a 15 percent increase over $488 million in Q3-2024. The total consisted of $518 million ...
Samsung Bioepis to Commercialize Byooviz in Europe Starting in January 2026
South Korea’s Samsung Bioepis announced Oct. 29 that it would assume responsibility for the marketing of Byooviz (ranibizumab), a Lucentis biosimilar, in Europe upon the transfer of commercial righ...
UK Accepts Conditional Marketing Application for Belite Bio’s Tinlarebant in Stargardt
Belite Bio announced Nov. 2 that the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) had agreed to accept a conditional marketing authorization application for oral tinlarebant for ...
FDA Clears Way for US Patient to Receive GenSight’s Lumevoq for LHON
France’s GenSight Biologics announced Oct. 30 that the FDA had granted permission for a single patient in the US to be treated with GS010, also known as Lumevoq, GenSight’s intravitreal gene therap...
Outlook Resubmits BLA to US FDA for Ophthalmic Bevacizumab (Lytenava)
Outlook Therapeutics reported Nov. 3 that it had resubmitted its biologics license application (BLA) to the US FDA for ONS-5010 (Lytenava), an ophthalmic formulation of bevacizumab for wet age-rela...
Visara Licenses Retinal Candidate to Everest for Greater China, Other Asian Countries
NovaBridge Biosciences announced Oct. 29 that its ophthalmic subsidiary, Visara, had licensed retinal treatment candidate VIS-101 to Everest Medicines for greater China, Singapore, South Korea, and...
Roche Reports Mixed Phase III Data for Vamikibart in Uveitic Macular Edema
Swiss drugmaker Roche reported on Oct. 16 mixed Phase III results for vamikibart, an IL-6 inhibitor being developed to address inflammation in uveitic macular edema (UME). Vamikibart, if approved, ...
US FDA Rejects Sydnexis’ Atropine Drop for Pediatric Myopia
Sydnexis announced Oct. 23 that the US FDA had issued a complete response letter rejecting the company’s new drug application (NDA) for SYD-101, a low-dose atropine formulation to slow the progress...
Lilly to Acquire Adverum in Deal Worth Up to $262 Million
Drugmaker Eli Lilly announced Oct. 24 that it would acquire Adverum Biotechnologies, developer of Ixo-vec, a Phase III intravitreal gene therapy candidate targeting wet age-related macular degenera...
STAAR Moves Shareholder Vote on Alcon Acquisition to Dec. 3
STAAR Surgical on Oct. 27 postponed until Dec. 3 its special meeting of shareholders to vote on Alcon’s acquisition of the company. STAAR also set a new record date of Oct. 24. Stockholders who hel...
Q3-2025 Ophthalmic Revenue Roundup for Bausch + Lomb, Roche, Regeneron, Novartis
Bausch + Lomb reported Oct. 29 that its Q3-2025 revenue totaled $1.3 billion, a 7 percent increase over $1.2 billion in Q3-2024. Ophthalmic pharmaceuticals segment revenue was $330 million, an 8 pe...
US FDA Again Rejects Xbrane’s Ranibizumab Biosimilar Candidate
Sweden’s Xbrane Biopharma announced Oct. 19 that the US FDA had issued a complete response letter rejecting the company’s resubmitted biologics license application (BLA) for its Lucentis (ranibizum...
Want to Read the Full Article?
Already Have an Account?
Register A Corporate Account
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.